Patents by Inventor Mildred L. Kaufman

Mildred L. Kaufman has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Oxy-cyanoquinolinone PDE9 inhibitors
    Patent number: 10370337
    Abstract: The present invention is directed to oxycyanoquinolinone compounds which may be useful as therapeutic agents for the treatment of central nervous system disorders associated with phosphodiesterase 9 (PDE9). The present invention also relates to the use of such compounds for treating neurological and psychiatric disorders, such as schizophrenia, psychosis or Huntington's disease, and those associated with striatal hypofunction or basal ganglia dysfunction.
    Type: Grant
    Filed: July 27, 2016
    Date of Patent: August 6, 2019
    Assignee: Merck, Sharp & Dohme Corp.
    Inventors: Antonella Converso, Mildred L. Kaufman, Kevin Rodzinak
  • OXY-CYANOQUINOLINONE PDE9 INHIBITORS
    Publication number: 20180258046
    Abstract: The present invention is directed to oxycyanoquinolinone compounds which may be useful as therapeutic agents for the treatment of central nervous system disorders associated with phosphodiesterase 9 (PDE9). The present invention also relates to the use of such compounds for treating neurological and psychiatric disorders, such as schizophrenia, psychosis or Huntington's disease, and those associated with striatal hypofunction or basal ganglia dysfunction.
    Type: Application
    Filed: July 27, 2016
    Publication date: September 13, 2018
    Applicant: Merck Sharp & Dohme Corp.
    Inventors: ANTONELLA CONVERSO, MILDRED L. KAUFMAN, KEVIN RODZINAK
  • Hexahydrocyclopentyl[f]indazole sulfonamides and derivatives thereof as selective glucocorticoid receptor modulators
    Patent number: 8299048
    Abstract: The present invention is directed to hexahydrocyclopentylf]indazole carboxamides and derivatives thereof as selective glucocorticoid receptor ligands useful for treating a variety of autoimmune and inflammatory diseases or conditions. Pharmaceutical compositions and methods of use are also included.
    Type: Grant
    Filed: February 24, 2009
    Date of Patent: October 30, 2012
    Assignee: Merck Sharp & Dohme Corp.
    Inventors: William P. Dankulich, Mildred L. Kaufman, Danielle M. McMaster, Robert S. Meissner, Helen J. Mitchell
  • HEXAHYDROCYCLOPENTYL[f]INDAZOLE SULFONAMIDES AND DERIVATIVES THEREOF AS SELECTIVE GLUCOCORTICOID RECEPTOR MODULATORS
    Publication number: 20110105440
    Abstract: The present invention is directed to hexahydrocyclopentylf]indazole carboxamides and derivatives thereof as selective glucocorticoid receptor ligands useful for treating a variety of autoimmune and inflammatory diseases or conditions. Pharmaceutical compositions and methods of use are also included.
    Type: Application
    Filed: February 24, 2009
    Publication date: May 5, 2011
    Inventors: William P. Dankulich, Mildred L. Kaufman, Danielle M. McMaster, Robert S. Meissner, Helen J. Mitchell
  • 17-acetamido-4-azasteroid derivatives as androgen receptor modulators
    Patent number: 7696217
    Abstract: Compounds of structural formula I are modulators of the androgen receptor (AR) in a tissue selective manner. They are useful as agonists of the androgen receptor in bone and/or muscle tissue while antagonizing the AR in the prostate of a male patient or in the uterus of a female patient.
    Type: Grant
    Filed: June 25, 2004
    Date of Patent: April 13, 2010
    Assignee: Merck Sharp & Dohme Corp.
    Inventors: William P. Dankulich, Mildred L. Kaufman, Robert S. Meissner, Helen J. Mitchell
  • 17-acetamido-4-azasteroid derivatives as androgen receptor modulators
    Patent number: 7482357
    Abstract: Compounds of structural formula I are modulators of the androgen receptor (AR) in a tissue selective manner. These compounds are useful in the enhancement of weakened muscle tone and the treatment of conditions caused by androgen deficiency or which can be ameliorated by androgen administration, including osteoporosis, osteopenia, glucocorticoid-induced osteoporosis, periodontal disease, bone fracture, bone damage following bone reconstructive surgery, sarcopenia, frailty, aging skin, male hypogonadism, postmenopausal symptoms in women, atherosclerosis, hypercholesterolemia, hyperlipidemia, obesity, aplastic anemia and other hematopoietic disorders, inflammatory arthritis and joint repair, HIV-wasting, prostate cancer, benign prostatic hyperplasia (BPH), cancer cachexia, Alzheimer's disease, muscular dystrophies, cognitive decline, sexual dysfunction, sleep apnea, depression, premature ovarian failure, and autoimmune disease, alone or in combination with other active agents.
    Type: Grant
    Filed: June 25, 2004
    Date of Patent: January 27, 2009
    Assignee: Merck & Co., Inc.
    Inventors: William P. Dankulich, Mildred L. Kaufman, Robert S. Meissner, Helen J. Mitchell
  • 17-Heterocyclic-4-azasteroid derivatives as androgen receptor modulators
    Patent number: 7446110
    Abstract: Compounds of structural formula I are modulators of the androgen receptor (AR) in a tissue selective manner.
    Type: Grant
    Filed: September 2, 2004
    Date of Patent: November 4, 2008
    Assignee: Merck & Co., Inc.
    Inventors: Mildred L. Kaufman, Robert S. Meissner, Helen J. Mitchell